MedTrace Logo

Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes

NCT06739707 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-20

No results posted yet for this study

Summary

A Multiple Dose, Randomized, Placebo-controlled, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered MD-18 for healthy subjects with overweight or obesity

Conditions

  • Healthy Volunteer

Interventions

DRUG

Placebo

Placebo administered subcutaneously to healthy individuals with overweight or obesity.

DRUG

MD-18

MD-18 administered subcutaneously to healthy individuals with overweight or obesity.

Sponsors & Collaborators

  • Cohen Global, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06739707 on ClinicalTrials.gov